A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)

[摘要] Purpose:The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-linechemotherapy in patients with locally advanced and/or metastatic adult STS.Patients and Methods:Eighteen patients were treated with epirubicin 30 mg/m2on days 1 to 3 and docetaxel 100 mg/m2onday 1 every 3 weeks.Results:Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%)patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3–48 months) and the mediantime to disease progression was 4 months (range, 2–45 months). Grade ≥ 3 neutropenia occurred in 88% and neutropenicfever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred.Discussion:Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients withadvanced STS.

[学科分类] 肿瘤学